LRRFIP2 and cancer: Since ACTR is known to be often overexpressed in many cancer cells and primary tumors, including breast, ovarian, gastric, and prostate cancers55–58, our findings show the possibility that tumor promoting activity of ACTR is due to the expression level of LRRFIP2 variant 3.